

Cell technology, cell therapy, tissue engineering and gene therapy in Japan

Technology developments, competitive situation and regulations. A primer of business opportunities for European stakeholders

March - 2015

Rolf Schmid



Contents

1. Terms used in this report	3
2. Introduction	5
3. Japan's cell-technology related research academic landscape	7
3.1 CiRA, iCEMs and Institute of Frontier Medical Sciences, Kyoto University	7
3.2 RIKEN Center for Developmental Biology, Kobe	7
3.3 University of Tokyo	8
3.4 Tokyo Medical and Dental University	8
3.5 Other academic groups	8
3.6 Hospitals	9
4. The Japanese Society for Regenerative Medicine	9
5. Companies (selection)	10
5.1 Dedicated SMEs	10
5.2 Established major Japanese companies active in cell technology	11
6. Government	13
6.1 The Ministry of Health, Labor and Welfare, MHLW	13
6.2 Ministry of Education MEXT and Japan Science and Technology Agency JST	15
6.3 Ministry of Economics, Trade and Industry METI and its project agency NEDO	16
7. Gene therapy	18
7.1 Academic research	18
7.2 Japan Society for Gene Therapy	19
7.3 Companies	19
7.4 Regulations	19
8. Comparison of pertinent regulations in Japan, Europe and the USA	20
9. Opportunities, access points and regulatory hurdles for European SMEs	20
10. Literature	21